A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A Phase II clinical trial of patients ...
Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
The Brighterside of News on MSN
Study finds low-dose CAR T therapy can drive complete cancer remission
A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...
Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...
Cellenkos receives US FDA clearance to initiate phase 1b/2a trial of CK0802 in steroid-refractory graft-versus-host disease: Houston Thursday, May 7, 2026, 18:00 Hrs [IST] Cellenk ...
Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host ...
MedPage Today on MSN
Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial
Disease-free survival of 96% with no severe GVHD in acute leukemia, other blood cancers ...
Please provide your email address to receive an email when new articles are posted on . Over 65% of patient-reported treatment responses agreed with clinicians’ evaluations, whereas 34.4% did not.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results